CNSP

CNS Pharmaceuticals Inc

CNSP, USA

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

https://www.cnspharma.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
CNSP
stock
CNSP

CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 3.3% – What’s Next? Defense World

Read more →
CNSP
stock
CNSP

(CNSP) Movement Within Algorithmic Entry Frameworks Stock Traders Daily

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$20

Analyst Picks

Strong Buy

1

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.01

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.02

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-32.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.12 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.20

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.86% of the total shares of CNS Pharmaceuticals Inc

1.

UBS Group AG

(0.3478%)

since

2025/03/31

2.

Fidelity Extended Market Index

(0.2311%)

since

2025/07/31

3.

Spartan Extended Market Index Pool F

(0.1415%)

since

2025/07/31

4.

Tower Research Capital LLC

(0.0741%)

since

2025/03/31

5.

Spartan Total Market Index Pool G

(0.035%)

since

2025/07/31

6.

Fidelity Series Total Market Index

(0.0242%)

since

2025/07/31

7.

BARRETT & COMPANY, INC.

(0.0015%)

since

2025/06/30

8.

Mccormack Advisors International

(0.0006%)

since

2025/03/31

9.

SBI Securities Co Ltd

(0.0002%)

since

2025/06/30

10.

Bank of America Corp

(0.0001%)

since

2025/03/31

11.

Goldman Sachs Group Inc

(0%)

since

2025/03/31

12.

Connective Capital Management LLC

(0%)

since

2025/03/31

13.

Ground Swell Capital, LLC

(0%)

since

2025/06/30

14.

Integrated Wealth Concepts LLC

(0%)

since

2025/03/31

15.

Jane Street Group LLC

(0%)

since

2025/03/31

16.

Citadel Advisors Llc

(0%)

since

2025/03/31

17.

Geode Capital Management, LLC

(0%)

since

2025/03/31

18.

Synergy Investment Management, LLC

(0%)

since

2025/03/31

19.

Two Sigma Investments LLC

(0%)

since

2025/03/31

20.

Virtu Financial LLC

(0%)

since

2025/03/31

21.

XTX Topco Ltd

(0%)

since

2025/03/31

22.

HRT FINANCIAL LLC

(0%)

since

2025/03/31

23.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0%)

since

2024/12/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-5.76

EPS Estimate

-6.63

EPS Difference

0.87

Surprise Percent

13.1222%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(9)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(4.5)
Net Net
Strong Net-Net(8)
Quality
Low Quality Business(2.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.